TOBRAMYCIN OPHTHALMIC SOLUTION USP, 0.3 %

Manufacturer
Belcher Pharmaceuticals, LLC | Gland Pharma Limited
Effective date
2025-02-11
Label type
Human Prescription Drug Label
Version
2
Source
full-release
Hydrated at
2026-05-31 21:25:38

Label at a glance#

ProductTobramycin
Active ingredientTOBRAMYCIN
Label structure10 sections

Indications and uses

Tobramycin ophthalmic solution USP, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution USP, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL of tobramycin ophthalmic solution USP, 0.3% contains: Active: tobramycin 0.3 % (3 mg). Preservative: benzalkonium chloride 0.01 % (0.1 mg). Inactives: boric acid, sodium sulfate decahydrate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution USP, 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is:

tobramycinstructuretobramycinstructure

Molecular Weight = 467.52
Molecular Formula: C18H37N5O9


Chemical name:
O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo- hexopyranosyl-(1→6)]-2-deoxy-L-streptamine.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.


Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tobramycin ophthalmic solution USP, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution USP, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tobramycin ophthalmic solution USP, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients.Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution USP, 0.3% occurs, discontinue use.

PRECAUTIONS:

PRECAUTIONS SECTION

General: As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular infection.


Information for Patients:
Do not touch dropper tip to any surface, as this may contaminate the solution.

Pregnancy: Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.


Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution.

To report SUSPECTED ADVERSE REACTIONS, contact Belcher Pharmaceuticals, LLC at 1-727-471-0850 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Postmarketing Experience: Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

HOW SUPPLIED:

HOW SUPPLIED SECTION

5 mL sterile solution supplied in opaque white low density polyethylene bottle which is closed with natural low density polyethylene nozzle and then with Tan colored high density polyethylene cap as follows:

5 mL containing tobramycin 0.3% (3 mg/mL)…. NDC 62250-110-01

Storage:  Store at 2°C to 25°C (36°F to 77°F).

After opening, Tobramycin Ophthalmic Solution, USP 0.3% can be used until the expiration date on the bottle.

Distributed by:

Belcher Pharmaceuticals, LLC

6911 Bryan Dairy Road,

Largo, FL 33777 USA

Made in India

January 2024

L100I                                  R-2401

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Bottle Label:

NDC 62250-110-01

Tobramycin Ophthalmic solution, USP 0.3%

Sterile 5 mL Rx Only

tobramycinlabeltobramycinlabel

Bottle Carton:

NDC 62250-110-01

Tobramycin Ophthalmic solution, USP 0.3%

Sterile 5 mL Rx Only

tobramycincartontobramycincarton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313415tobramycin 0.3 % Ophthalmic SolutionPSN2
313415tobramycin 3 MG/ML Ophthalmic SolutionSCD2
313415tobramycin 0.3 % Ophthalmic SolutionSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TOBRAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f297c7c1-845a-4369-8c02-c51b92d6ae8eProduct name320240725
551d952d-4ce2-24f0-9ab0-630ad9aae596Product name220231211
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9cfa145f-dbe9-bc02-83c2-692786ef6676Product name920210928
2f9713b8-5e7e-bbcc-b364-1b2c27a63796Product name420210903
32a533bc-01c7-2b9f-bbf7-ecfb0d964277Product name420210625
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
9f5124fb-08b0-4c3e-8e12-a1a6ff310cbaProduct name120150309
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
745a62af-e1c0-4ca3-6d6e-2b6455b903beProduct name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
aa1cd319-ece7-51f7-3a9d-52a64f5f4e81Product name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508
ef5b7aed-2b01-3ba8-5a1c-3bc9c9f03bb1Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
62250-110-01Tobramycin1 in 1 CARTONSOLUTION/ DROPS12
62250-110-01Tobramycin5 mL in 1 BOTTLE, PLASTICSOLUTION/ DROPS52

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
62250-110TOBRAMYCIN SOLUTION/ DROPS [BELCHER PHARMACEUTICALS, LLC]2Current NDC, 2 package rows20250213_17b5b083-79ab-46b5-bed6-866e5415c623.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
62250-11062250-110-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A212628-001TOBRAMYCINTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A212628-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09d4dbc9d85df4…
2026-10-15 13:18:302026-09A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09c2088c7a36db…
2026-09-14 22:38:342026-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0984e616aacf4f…
2026-08-18 06:07:402026-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-091e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-098072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-095d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-094b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-0987673890dc5c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-096a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-091c564ffb4f44…
2023-12-20 04:57 UTC2023-12A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-099b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093f0d92c62455…
2023-05-13 08:27 UTC2023-05A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09053a50430f4f…
2023-01-26 05:58 UTC2023-01A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-093a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212628-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2021-03-09a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A212628-001AT1d4dbc9d85df4…
2026-10-15 13:18:302026-09A212628-001AT1c2088c7a36db…
2026-09-14 22:38:342026-08A212628-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A212628-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212628-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212628-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A212628-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212628-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212628-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212628-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212628-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212628-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212628-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212628-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212628-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212628-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212628-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212628-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A212628-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A212628-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A212628-001AT14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A212628-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A212628-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A212628-001AT187673890dc5c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A212628-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A212628-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A212628-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A212628-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A212628-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A212628-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A212628-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A212628-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A212628-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A212628-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A212628-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A212628-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A212628-001AT1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212628-001AT1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TobramycinTOBRAMYCINBelcher Pharmaceuticals, LLC17b5b083-79ab-46b5-bed6-866e5415c6232025-02-11Warnings, Adverse reactionsExact identifier
ndc (package): 62250-110-01
ndc (product): 62250-110
ndc11 (package): 62250011001
spl id: f2495e4f-4ffe-4e14-bcb3-f72f1da932a6
spl set id: 17b5b083-79ab-46b5-bed6-866e5415c623

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.